<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of adults with idiopathic cutaneous small vessel vasculitis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of adults with idiopathic cutaneous small vessel vasculitis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of adults with idiopathic cutaneous small vessel vasculitis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nicole Fett, MD, MSCE</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey Callen, MD, FACP, FAAD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 11, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H25558599"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cutaneous small vessel vasculitis (CSVV) is a disorder characterized by leukocytoclastic vasculitis involving the small blood vessels in the skin. By definition, vasculitis affecting other organ systems must be absent, and direct immunofluorescence should not reveal immunoglobulin A (IgA) predominance. CSVV may develop in association with a wide variety of factors, including drugs, infections, vaccines, systemic disease, or malignancy. An inciting factor is not detected in around one-third to one-half of patients. Such patients are designated here as having idiopathic CSVV.</p><p>Idiopathic CSVV often resolves within a few weeks, and thus, the management of most patients involves confirming the lack of an identifiable cause and the alleviation of symptoms. Systemic immunomodulatory therapy to arrest the disease process is usually reserved for the subset of patients who develop complications, such as hemorrhagic bullae, ulceration, or chronic or recurrent disease  (<a class="graphic graphic_algorithm graphicRef134273" href="/z/d/graphic/134273.html" rel="external">algorithm 1</a>).</p><p>The management of patients with idiopathic CSVV will be reviewed here. The evaluation of patients with cutaneous lesions of vasculitis and the clinical features and treatment of specific disorders that may present with vasculitis involving small vessels of the skin are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13769.html" rel="external">"Evaluation of adults with cutaneous lesions of vasculitis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8241.html" rel="external">"Overview of cutaneous small vessel vasculitis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8218.html" rel="external">"Urticarial vasculitis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6407.html" rel="external">"IgA vasculitis (Henoch-Schönlein purpura): Management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8228.html" rel="external">"Treatment of rheumatoid vasculitis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4346.html" rel="external">"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Treatment and prognosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3070.html" rel="external">"Mixed cryoglobulinemia syndrome: Treatment and prognosis"</a>.)</p><p></p><p class="headingAnchor" id="H368130"><span class="h1">TERMINOLOGY AND DEFINITIONS</span></p><p class="headingAnchor" id="H593829380"><span class="h2">Cutaneous small vessel vasculitis</span><span class="headingEndMark"> — </span>Cutaneous small vessel vasculitis (CSVV) is characterized by the presence of cutaneous lesions in conjunction with histopathologic evidence for a leukocytoclastic vasculitis involving the capillaries, venules, and arterioles in the skin. Although palpable purpura are the most common associated skin manifestations, other lesions such as petechiae, hemorrhagic bullae, ulcers, and urticaria may also develop  (<a class="graphic graphic_picture graphicRef56272 graphicRef65932 graphicRef58626 graphicRef57440" href="/z/d/graphic/56272.html" rel="external">picture 1A-D</a>). The skin lesions are often most prevalent on the lower legs and other dependent areas.</p><p>Other terms that have been used to refer to "cutaneous small vessel vasculitis" include "cutaneous leukocytoclastic vasculitis," "cutaneous leukocytoclastic angiitis," and "cutaneous necrotizing venulitis," all of which refer to the characteristic histopathologic findings in CSVV. The term "hypersensitivity vasculitis" has also been used to refer to CSVV but is most appropriately applied to CSVV caused by a known drug or infection. (See  <a class="medical medical_review" href="/z/d/html/8241.html" rel="external">"Overview of cutaneous small vessel vasculitis", section on 'Definitions'</a>.)</p><p>The 2012 Revised International Chapel Hill Consensus Conference Nomenclature classifies CSVV as a single-organ vasculitis, as does the dermatologic addendum to the 2012 Revised International Chapel Hill Consensus Conference [<a href="#rid1">1,2</a>].</p><p class="headingAnchor" id="H346219094"><span class="h2">Idiopathic cutaneous small vessel vasculitis</span><span class="headingEndMark"> — </span>Idiopathic CSVV is CSVV that is limited to the skin and lacks an identifiable cause. In addition, direct immunofluorescence should not reveal IgA predominance, a finding supportive of IgA vasculitis. (See  <a class="medical medical_review" href="/z/d/html/6406.html" rel="external">"IgA vasculitis (Henoch-Schönlein purpura): Clinical manifestations and diagnosis"</a>.)</p><p>A wide variety of factors can induce CSVV, including drugs, infections, systemic diseases, vaccines, malignancy, and, rarely, dietary factors [<a href="#rid3">3,4</a>]. In such cases, removal of the underlying cause may result in the resolution of CSVV [<a href="#rid5">5-7</a>]. Idiopathic CSVV, which accounts for 30 to 60 percent of cases, is a diagnosis of exclusion that can only be made when clinical history, review of recent medications, and clinical and laboratory investigations fail to yield both an underlying cause and the presence of systemic vasculitis [<a href="#rid3">3,8</a>]. In addition, systemic involvement should be excluded prior to making this diagnosis, since a more aggressive approach to therapy is usually indicated in patients with internal disease. (See  <a class="medical medical_review" href="/z/d/html/13769.html" rel="external">"Evaluation of adults with cutaneous lesions of vasculitis", section on 'Evaluation for etiology and extracutaneous involvement'</a>.)</p><p class="headingAnchor" id="H1085503383"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>In most patients with cutaneous small vessel vasculitis (CSVV), the condition is self-limited and spontaneously resolves within two to four weeks [<a href="#rid4">4,8</a>]. In patients with self-limited disease, new lesion formation usually continues to occur during the first one to two weeks of the disease process. Chronic or recurrent disease occurs in approximately 10 percent of patients [<a href="#rid3">3,4,9</a>].</p><p>Postinflammatory hyperpigmentation and red-brown hemosiderin deposits in the skin that are secondary to the breakdown of extravasated erythrocytes commonly remain after an episode of CSVV. These lesions tend to resolve slowly over time; several months or more may be required for resolution.</p><p class="headingAnchor" id="H368147"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>The clinical presentation of idiopathic cutaneous small vessel vasculitis (CSVV) influences the approach to treatment  (<a class="graphic graphic_algorithm graphicRef134273" href="/z/d/graphic/134273.html" rel="external">algorithm 1</a>). The management of patients with acute, uncomplicated disease differs from those with complicated, chronic, or recurrent idiopathic CSVV.</p><p class="headingAnchor" id="H368515"><span class="h2">Acute and uncomplicated idiopathic cutaneous small vessel vasculitis</span><span class="headingEndMark"> — </span>Acute and uncomplicated CSVV may be considered CSVV with:</p><p class="bulletIndent1"><span class="glyph">●</span>Duration of less than four weeks</p><p class="bulletIndent1"><span class="glyph">●</span>Palpable purpura or petechiae <strong>without </strong>blisters, skin necrosis, or ulceration</p><p class="bulletIndent1"><span class="glyph">●</span>No history of prior occurrence</p><p></p><p>Due to the high likelihood for spontaneous resolution, treatment to suppress the vasculitic process is not necessary in patients who present with acute and uncomplicated idiopathic CSVV  (<a class="graphic graphic_algorithm graphicRef134273" href="/z/d/graphic/134273.html" rel="external">algorithm 1</a>). However, some of these patients experience bothersome pruritus, pain, or local edema and may benefit from interventions that improve these symptoms.</p><p>Clinical experience suggests that the following measures can be beneficial [<a href="#rid3">3</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rest, leg elevation, and compression stockings </strong>– Disease may be exacerbated by exercise or prolonged maintenance of affected areas in dependent positions [<a href="#rid3">3</a>]. Leg elevation and use of compression stockings may decrease immune complex deposition in the lower extremities, thereby decreasing the progression of vasculitic skin lesions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonsteroidal anti-inflammatory drugs (NSAIDs)</strong> – NSAIDs may be useful for pain management. (See  <a class="medical medical_review" href="/z/d/html/7993.html" rel="external">"NSAIDs: Therapeutic use and variability of response in adults", section on 'General principles'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral antihistamines </strong>– Antihistamines may help to suppress pruritus. (See  <a class="medical medical_review" href="/z/d/html/131632.html" rel="external">"Pruritus: Therapies for generalized pruritus", section on 'Role of antihistamines'</a>.)</p><p></p><p class="headingAnchor" id="H25558627"><span class="h2">Complicated, chronic, or recurrent idiopathic cutaneous small vessel vasculitis</span><span class="headingEndMark"> — </span>Complicated or chronic CSVV may be considered CSVV with:</p><p class="bulletIndent1"><span class="glyph">●</span>Associated hemorrhagic blisters, skin necrosis, or ulceration</p><p class="bulletIndent1"><span class="glyph">●</span>Active disease that persists for more than four weeks</p><p class="bulletIndent1"><span class="glyph">●</span>A history of prior occurrence</p><p></p><p class="headingAnchor" id="H1012567606"><span class="h3">Whom to treat</span><span class="headingEndMark"> — </span>Treatment aimed at arresting the disease process is indicated in patients with idiopathic CSVV complicated by the presence of hemorrhagic blisters, cutaneous necrosis, or ulceration, as these manifestations may lead to secondary infections, chronic wounds, and scarring  (<a class="graphic graphic_algorithm graphicRef134273" href="/z/d/graphic/134273.html" rel="external">algorithm 1</a>).</p><p>Patients with chronic idiopathic CSVV (active disease that persists for more than four weeks) or recurring disease are also candidates for therapeutic intervention. However, when chronic or recurrent disease is asymptomatic and patients are not bothered by the appearance of skin lesions, deferring treatment is a reasonable alternative.</p><p>Patients with chronic idiopathic CSVV who do not proceed with treatment should be re-evaluated every three to six months to ensure disease stability. The evaluation should consist of a directed review of systems, physical examination, and urinalysis to detect signs of worsening cutaneous involvement or new systemic involvement. Additional testing should be performed only if symptoms are present. (See  <a class="medical medical_review" href="/z/d/html/13769.html" rel="external">"Evaluation of adults with cutaneous lesions of vasculitis", section on 'Review of systems'</a>.)</p><p class="headingAnchor" id="H2646381493"><span class="h3">Initial therapy</span><span class="headingEndMark"> — </span>Systemic immunomodulatory drugs are the mainstays of treatment for patients with complicated or chronic idiopathic CSVV  (<a class="graphic graphic_algorithm graphicRef134273" href="/z/d/graphic/134273.html" rel="external">algorithm 1</a>). Our approach to these patients involves the initial use of a short course of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> in an attempt to abruptly suppress the disease process, followed by the use of <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> and/or <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> in patients who continue to have active disease. If the response to this regimen is inadequate, we consider the use of immunosuppressive agents. (See <a class="local">'Relapse or persistent disease'</a> below and <a class="local">'Refractory disease'</a> below.)</p><p>Much of the data used to guide the approach to the treatment of idiopathic CSVV are derived from case reports and small case series of patients with cutaneous leukocytoclastic vasculitis associated with a predisposing factor, with or without concomitant extracutaneous disease. The paucity of data on the efficacy of treatments precludes definitive conclusions on the efficacy of any specific therapy.</p><p class="headingAnchor" id="H58265601"><span class="h4">Systemic glucocorticoids</span><span class="headingEndMark"> — </span>Systemic glucocorticoids are the most commonly utilized agents for the management of acute single episodes of CSVV [<a href="#rid3">3</a>]. In our experience, the vast majority of patients with idiopathic CSVV improve during therapy:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration </strong>– We typically initiate treatment with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> at a dose of 0.5 mg/kg per day of ideal body weight until new lesion formation ceases (usually one to two weeks). The initial prednisone dose typically falls between 20 and 40 mg per day. This is followed by a taper to treatment cessation over the course of three to six weeks. Improvement is often detectable within one week after starting therapy. Patients who do not respond to prednisone should be transitioned to a glucocorticosteroid-sparing agent, such as <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> or <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a>. (See <a class="local">'Relapse or persistent disease'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy </strong>– No randomized trials have evaluated the efficacy of systemic glucocorticoid therapy in CSVV, and the use of these agents is primarily based upon reports of efficacy from small series of patients with various forms of cutaneous leukocytoclastic vasculitis [<a href="#rid3">3,10-12</a>].</p><p></p><p class="headingAnchor" id="H3047709257"><span class="h3">Relapse or persistent disease</span><span class="headingEndMark"> — </span>For patients in whom disease recurs upon tapering or discontinuation of an initial course of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> or who do not respond adequately to prednisone, continuation of long-term prednisone is not recommended due to the risk for drug-related side effects [<a href="#rid13">13-17</a>]. Rather, such patients should be transitioned to glucocorticoid-sparing medications, such as <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> or <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a>  (<a class="graphic graphic_algorithm graphicRef134273" href="/z/d/graphic/134273.html" rel="external">algorithm 1</a>). If significant morbidity is likely to result from a disease flare, we continue prednisone at the lowest effective dose until the onset of action of the glucocorticoid-sparing agent. (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p><a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">Colchicine</a> or <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> are inhibitors of neutrophil function. Although the data to support the efficacy of these therapies are limited, a trial of these agents is reasonable prior to the use of more aggressive immunosuppressive therapies [<a href="#rid9">9</a>]. (See <a class="local">'Refractory disease'</a> below.)</p><p>In our experience, both <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> and <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> therapy are useful for decreasing the reliance on <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> in the majority of treated patients. We usually attempt treatment with colchicine first, due to the broader range of adverse effects associated with dapsone therapy.</p><p class="headingAnchor" id="H25558641"><span class="h4">Colchicine</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precautions</strong> – Caution is indicated for <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> therapy in patients with renal or hepatic impairment or who are taking a P-glycoprotein (P-gp) inhibitor  (<a class="graphic graphic_table graphicRef73326" href="/z/d/graphic/73326.html" rel="external">table 1</a>) or strong cytochrome P450 3A4 (CYP3A4) inhibitor  (<a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">table 2</a>) due to increased risk for toxicity. Colchicine is contraindicated in patients who have renal or hepatic impairment who are also taking a P-gp inhibitor or strong CYP3A4 inhibitor. (See  <a class="drug drug_general" href="/z/d/drug information/9293.html" rel="external">"Colchicine: Drug information"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration </strong>– <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">Colchicine</a> for CSVV is usually given as a 0.6 mg dose twice daily. Initial signs of response are typically observed within one to two weeks. Patients who respond typically continue treatment for a few months. (See <a class="local">'Duration of therapy'</a> below.)</p><p></p><p class="bulletIndent1">If no response is noted after one week, increasing the dose to 0.6 mg three times per day may be attempted. However, drug-related, gastrointestinal adverse effects, such as diarrhea, nausea, vomiting, and abdominal pain, often limit dose escalation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy </strong>– Data conflict on the efficacy of <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> in CSVV. An unblinded, randomized trial in which 41 patients with histopathologically confirmed cutaneous leukocytoclastic vasculitis (either idiopathic or associated with a predisposing factor) were treated for at least one month with either colchicine alone (0.5 mg twice daily) or topical emollients found no significant difference in efficacy between the two treatments [<a href="#rid18">18</a>]. The study included 16 patients who had been treated with other agents with variable responses, suggesting that an unspecified proportion of patients may have had refractory disease. </p><p></p><p class="bulletIndent1">In contrast to the randomized trial, case series and case reports have suggested that <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> therapy can be beneficial [<a href="#rid8">8,11,19-22</a>]. In one series, seven out of nine patients with chronic, biopsy-proven leukocytoclastic vasculitis who demonstrated improvement during treatment with colchicine had disease flares upon discontinuation of the drug and recurrent improvement with drug reinitiation [<a href="#rid20">20</a>].</p><p></p><p class="headingAnchor" id="H25558648"><span class="h4">Dapsone</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precautions </strong>– Clinicians who prescribe <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> must remain cognizant of the drug's potential adverse effects. Hemolytic anemia is a common consequence of treatment that occurs in all patients with varying severity, and close monitoring of hematologic status, especially early in the course of therapy, is essential. In particular, dapsone therapy should be avoided in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to a high risk for severe hemolytic anemia. Other potential adverse effects of dapsone include idiosyncratic agranulocytosis, a hypersensitivity syndrome, hepatitis, and peripheral motor neuropathy. (See  <a class="medical medical_review" href="/z/d/html/7111.html" rel="external">"Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency", section on 'Avoidance of unsafe drugs and chemicals'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration </strong>– If baseline laboratory studies, including a complete blood count, comprehensive metabolic panel to assess liver and renal function, and a G6PD assay are within normal limits, we typically begin treatment with 100 mg of <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> per day. Signs of improvement are often noted as early as one week after the initiation of therapy [<a href="#rid23">23</a>]. Patients who respond typically continue treatment for a few months. (See <a class="local">'Duration of therapy'</a> below.)</p><p></p><p class="bulletIndent1">Standard monitoring recommendations include a complete blood count once weekly during the first month of therapy and periodic monitoring of liver function tests. Obtaining complete blood counts and liver function tests every other week during the first month of therapy has seemed sufficient in the author's practice. Provided the drug dose remains stable, the frequency of these studies can then be reduced to once monthly for three to four months, followed by once every three to four months.</p><p></p><p class="bulletIndent1">For patients who fail to exhibit signs of improvement after two weeks at 100 mg of <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> per day, we increase the daily dose to 150 mg. If the response to 150 mg per day of dapsone is unsatisfactory, we proceed to immunosuppressive therapy. An alternative that we typically reserve for select patients with relatively mild, uncomplicated CSVV is a trial of combination therapy with dapsone and <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">pentoxifylline</a> prior to proceeding to immunosuppressive therapy. (See <a class="local">'Refractory disease'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy </strong>– Data in support of <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> use are limited to case reports in patients with various forms of cutaneous leukocytoclastic vasculitis [<a href="#rid23">23-31</a>]. As with <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a>, there are reports in which disease improved during treatment and recurred upon the discontinuation of dapsone therapy [<a href="#rid23">23,24</a>].</p><p></p><p class="bulletIndent1">The addition of <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">pentoxifylline</a> (400 mg three times daily) to <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> (100 mg per day) was associated with improvement of dapsone-resistant cutaneous leukocytoclastic vasculitis related to rheumatoid arthritis and urticarial vasculitis within two weeks in two patients [<a href="#rid32">32</a>]. However, additional studies are necessary to confirm the efficacy of the dapsone-pentoxifylline combination.</p><p></p><p class="headingAnchor" id="H1132622"><span class="h3">Refractory disease</span><span class="headingEndMark"> — </span>When disease persists despite treatment with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a>, and <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a>, we initiate systemic immunosuppressive therapy  (<a class="graphic graphic_algorithm graphicRef134273" href="/z/d/graphic/134273.html" rel="external">algorithm 1</a>). Because no high-quality studies have evaluated the efficacy of these agents for cutaneous vasculitis, patient-specific concerns for drug adverse effects and contraindications heavily influence treatment selection.</p><p>The immunosuppressive agents we most frequently prescribe for idiopathic CSVV are <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, and <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mycophenolate</strong><strong> mofetil </strong>– Data on the efficacy of <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil in CSVV are limited. Treatment with mycophenolate mofetil (1 to 1.5 g twice daily) led to the resolution of idiopathic CSVV within two months in a patient who improved only partially on <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> and <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> therapy [<a href="#rid33">33</a>]. Mycophenolate mofetil has also been associated with beneficial effects in a few patients with cutaneous leukocytoclastic vasculitis related to IgA vasculitis (Henoch-Schönlein purpura) or urticarial vasculitis [<a href="#rid34">34,35</a>]. (See  <a class="medical medical_review" href="/z/d/html/7990.html" rel="external">"Mycophenolate: Overview of use and adverse effects in the treatment of rheumatic diseases"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Azathioprine</strong><strong> </strong>– <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">Azathioprine</a> may be administered in doses of 0.5 to 2.5 mg/kg per day, with appropriate dosing dependent upon the patient's thiopurine methyltransferase (TPMT) enzyme activity [<a href="#rid36">36</a>]. Responses to therapy are typically evident within two months. (See  <a class="medical medical_review" href="/z/d/html/7994.html" rel="external">"Pharmacology and side effects of azathioprine when used in rheumatic diseases"</a> and  <a class="medical medical_review" href="/z/d/html/4058.html" rel="external">"Thiopurines: Pretreatment testing and approach to therapeutic drug monitoring for adults with inflammatory bowel disease"</a>.)</p><p></p><p class="bulletIndent1">Although a randomized trial in 19 patients with cutaneous leukocytoclastic vasculitis and rheumatoid arthritis failed to find significant benefit of treatment with <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> plus <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> when this regimen was compared with the continuation of arthritis regimens containing NSAIDs, <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a>, aurothioglucose, <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">penicillamine</a>, or <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a> [<a href="#rid37">37</a>], small case series have documented improvement in cutaneous leukocytoclastic vasculitis during azathioprine therapy [<a href="#rid11">11,38,39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methotrexate</strong><strong> </strong>– <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> (10 to 20 mg per week) has been reported to be effective in individual patients with cutaneous vasculitis related to autoimmune disorders, with responses often detected within four to eight weeks [<a href="#rid40">40-43</a>]. However, treatment with methotrexate has also been associated with the induction of cutaneous vasculitis [<a href="#rid44">44-46</a>]. (See  <a class="medical medical_review" href="/z/d/html/7509.html" rel="external">"Major side effects of low-dose methotrexate"</a>.)</p><p></p><p><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> may also be beneficial in some patients with cutaneous vasculitis. In a small, open-label study of patients with severe or refractory cutaneous vasculitis, a regimen containing cyclosporine (5 mg/kg per day) or cyclosporine followed by <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> therapy was linked to good responses in 5 out of 12 patients (follow-up period of 4 to 12 months) [<a href="#rid47">47</a>]. However, the development of renal toxicity may limit the duration of treatment with cyclosporine. (See  <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus"</a> and  <a class="medical medical_review" href="/z/d/html/7357.html" rel="external">"Cyclosporine and tacrolimus nephrotoxicity"</a>.)</p><p><a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">Cyclophosphamide</a>, an aggressive immunosuppressive agent used in the management of systemic vasculitis, is not typically prescribed for CSVV due to the possibility for serious, drug-related adverse effects, including infertility. (See  <a class="medical medical_review" href="/z/d/html/7987.html" rel="external">"General toxicity of cyclophosphamide in rheumatic diseases"</a>.)</p><p class="headingAnchor" id="H4022182074"><span class="h3">Duration of therapy</span><span class="headingEndMark"> — </span>The duration of <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a>, <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a>, and immunosuppressive treatment in patients with chronic or complicated CSVV varies. We typically attempt to discontinue therapy once existing lesions have healed and no new lesions have developed for two to three months. If lesions recur, treatment is reinitiated. The optimal regimen for discontinuing therapy in idiopathic CSVV is unknown; we typically decrease the dose of medication over the course of a few weeks and monitor for disease flares prior to complete drug cessation.</p><p class="headingAnchor" id="H294453"><span class="h3">Other therapies</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">Hydroxychloroquine</a> is a well-tolerated drug that has been reported to be effective in the treatment of urticarial vasculitis. The efficacy of hydroxychloroquine in other forms of idiopathic CSVV is unknown. (See  <a class="medical medical_review" href="/z/d/html/8218.html" rel="external">"Urticarial vasculitis", section on 'Treatment'</a>.)</p><p>Additional agents reported to be useful in individual patients with cutaneous leukocytoclastic vasculitis include <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> [<a href="#rid48">48</a>], <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> [<a href="#rid49">49</a>], <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">chlorambucil</a> [<a href="#rid50">50</a>], and intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> [<a href="#rid51">51</a>]. Topical corticosteroids are commonly used for the management of inflammatory skin diseases, but these agents have not been formally evaluated in the treatment of CSVV. In our experience, treatment with topical corticosteroids has not been beneficial.</p><p class="headingAnchor" id="H2289543667"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110743.html" rel="external">"Society guideline links: Vasculitis"</a>.)</p><p class="headingAnchor" id="H294555"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview </strong>– Cutaneous small vessel vasculitis (CSVV) is a vasculitic disorder characterized by involvement limited to the skin and histopathologic evidence for a leukocytoclastic vasculitis involving the capillaries, venules, and arterioles in the skin. Palpable purpura are the most common clinical manifestations.</p><p></p><p class="bulletIndent1">Idiopathic CSVV is CSVV for which an underlying cause cannot be identified. Idiopathic CSVV is a diagnosis of exclusion that accounts for 30 to 60 percent of cases of CSVV. (See <a class="local">'Terminology and definitions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute and uncomplicated idiopathic cutaneous small vessel vasculitis</strong> – Acute and uncomplicated idiopathic CSVV may be considered an initial episode of idiopathic CSVV that has persisted for less than four weeks and lacks blistering, skin necrosis, and ulceration.</p><p></p><p class="bulletIndent1">In most patients, idiopathic CSVV resolves spontaneously within a few weeks, negating the need for treatment to stop the disease process. For patients with acute, uncomplicated idiopathic CSVV, we suggest supportive care rather than systemic immunomodulatory treatment  (<a class="graphic graphic_algorithm graphicRef134273" href="/z/d/graphic/134273.html" rel="external">algorithm 1</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Supportive care focuses on the alleviation of symptoms and includes rest, leg elevation, compression stockings, and treatment for pain and pruritus. (See <a class="local">'Acute and uncomplicated idiopathic cutaneous small vessel vasculitis'</a> above and <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complicated, chronic, or recurrent idiopathic cutaneous small vessel vasculitis</strong> – Systemic immunomodulatory therapy to arrest disease activity is indicated for idiopathic CSVV complicated by blisters, skin necrosis, or ulcers  (<a class="graphic graphic_algorithm graphicRef134273" href="/z/d/graphic/134273.html" rel="external">algorithm 1</a>). Systemic immunomodulatory therapy is also appropriate for chronic (lasting more than four weeks) or recurrent idiopathic CSVV. Deferring treatment is a reasonable alternative for patients with asymptomatic chronic or recurrent CSVV who are not bothered by the skin lesions (see <a class="local">'Complicated, chronic, or recurrent idiopathic cutaneous small vessel vasculitis'</a> above and <a class="local">'Whom to treat'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial therapy </strong>– For patients with complicated, chronic, or recurrent idiopathic CSVV, we suggest <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> as the initial systemic therapy rather than other immunomodulatory therapies  (<a class="graphic graphic_algorithm graphicRef134273" href="/z/d/graphic/134273.html" rel="external">algorithm 1</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Prednisone (0.5 mg/kg per day of ideal body weight) is given until new lesion formation ceases (usually one to two weeks) and is subsequently tapered over three to six weeks. (See <a class="local">'Initial therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Relapse or persistent disease </strong>– The potential serious adverse effects of systemic glucocorticoid therapy limit the long-term use of this therapy. For patients who relapse upon tapering or discontinuation of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> or fail to respond adequately to prednisone, we suggest treatment with <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> or <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> rather than other immunomodulatory therapies  (<a class="graphic graphic_algorithm graphicRef134273" href="/z/d/graphic/134273.html" rel="external">algorithm 1</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We typically attempt treatment with colchicine first, due to the broader range of adverse effects associated with dapsone therapy. (See <a class="local">'Colchicine'</a> above and <a class="local">'Dapsone'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Refractory disease </strong>– Patients with CSVV refractory to <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a>, and <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> may benefit from immunosuppressive therapies, such as <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, or <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>. (See <a class="local">'Refractory disease'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65:1.</a></li><li><a class="nounderline abstract_t">Sunderkötter CH, Zelger B, Chen KR, et al. Nomenclature of Cutaneous Vasculitis: Dermatologic Addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheumatol 2018; 70:171.</a></li><li><a class="nounderline abstract_t">Russell JP, Gibson LE. Primary cutaneous small vessel vasculitis: approach to diagnosis and treatment. Int J Dermatol 2006; 45:3.</a></li><li><a class="nounderline abstract_t">Loricera J, Blanco R, Ortiz-Sanjuán F, et al. Single-organ cutaneous small-vessel vasculitis according to the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides: a study of 60 patients from a series of 766 cutaneous vasculitis cases. Rheumatology (Oxford) 2015; 54:77.</a></li><li><a class="nounderline abstract_t">Carlson JA, Cavaliere LF, Grant-Kels JM. Cutaneous vasculitis: diagnosis and management. Clin Dermatol 2006; 24:414.</a></li><li><a class="nounderline abstract_t">Lotti T, Ghersetich I, Comacchi C, Jorizzo JL. Cutaneous small-vessel vasculitis. J Am Acad Dermatol 1998; 39:667.</a></li><li><a class="nounderline abstract_t">Lunardi C, Bambara LM, Biasi D, et al. Elimination diet in the treatment of selected patients with hypersensitivity vasculitis. Clin Exp Rheumatol 1992; 10:131.</a></li><li><a class="nounderline abstract_t">Martinez-Taboada VM, Blanco R, Garcia-Fuentes M, Rodriguez-Valverde V. Clinical features and outcome of 95 patients with hypersensitivity vasculitis. Am J Med 1997; 102:186.</a></li><li><a class="nounderline abstract_t">Fiorentino DF. Cutaneous vasculitis. J Am Acad Dermatol 2003; 48:311.</a></li><li><a class="nounderline abstract_t">Sanchez NP, Winkelmann RK, Schroeter AL, Dicken CH. The clinical and histopathologic spectrums of urticarial vasculitis: study of forty cases. J Am Acad Dermatol 1982; 7:599.</a></li><li><a class="nounderline abstract_t">Callen JP, af Ekenstam E. Cutaneous leukocytoclastic vasculitis: clinical experience in 44 patients. South Med J 1987; 80:848.</a></li><li><a class="nounderline abstract_t">O'Loughlin S, Schroeter AL, Jordon RE. Chronic urticaria-like lesions in systemic lupus erythematosus. A review of 12 cases. Arch Dermatol 1978; 114:879.</a></li><li><a class="nounderline abstract_t">Cupps TR, Springer RM, Fauci AS. Chronic, recurrent small-vessel cutaneous vasculitis. Clinical experience in 13 patients. JAMA 1982; 247:1994.</a></li><li><a class="nounderline abstract_t">Caplan A, Fett N, Rosenbach M, et al. Prevention and management of glucocorticoid-induced side effects: A comprehensive review: Ocular, cardiovascular, muscular, and psychiatric side effects and issues unique to pediatric patients. J Am Acad Dermatol 2017; 76:201.</a></li><li><a class="nounderline abstract_t">Caplan A, Fett N, Rosenbach M, et al. Prevention and management of glucocorticoid-induced side effects: A comprehensive review: Infectious complications and vaccination recommendations. J Am Acad Dermatol 2017; 76:191.</a></li><li><a class="nounderline abstract_t">Caplan A, Fett N, Rosenbach M, et al. Prevention and management of glucocorticoid-induced side effects: A comprehensive review: Gastrointestinal and endocrinologic side effects. J Am Acad Dermatol 2017; 76:11.</a></li><li><a class="nounderline abstract_t">Caplan A, Fett N, Rosenbach M, et al. Prevention and management of glucocorticoid-induced side effects: A comprehensive review: A review of glucocorticoid pharmacology and bone health. J Am Acad Dermatol 2017; 76:1.</a></li><li><a class="nounderline abstract_t">Sais G, Vidaller A, Jucglà A, et al. Colchicine in the treatment of cutaneous leukocytoclastic vasculitis. Results of a prospective, randomized controlled trial. Arch Dermatol 1995; 131:1399.</a></li><li><a class="nounderline abstract_t">Hazen PG, Michel B. Management of necrotizing vasculitis with colchicine. Improvement in patients with cutaneous lesions and Behcet's syndrome. Arch Dermatol 1979; 115:1303.</a></li><li><a class="nounderline abstract_t">Callen JP. Colchicine is effective in controlling chronic cutaneous leukocytoclastic vasculitis. J Am Acad Dermatol 1985; 13:193.</a></li><li><a class="nounderline abstract_t">Plotnick S, Huppert AS, Kantor G. Colchicine and leukocytoclastic vasculitis. Arthritis Rheum 1989; 32:1489.</a></li><li><a class="nounderline abstract_t">Wiles JC, Hansen RC, Lynch PJ. Urticarial vasculitis treated with colchicine. Arch Dermatol 1985; 121:802.</a></li><li><a class="nounderline abstract_t">Fredenberg MF, Malkinson FD. Sulfone therapy in the treatment of leukocytoclastic vasculitis. Report of three cases. J Am Acad Dermatol 1987; 16:772.</a></li><li><a class="nounderline abstract_t">Cribier B, Cuny JF, Schubert B, et al. Recurrent annular erythema with purpura: a new variant of leucocytoclastic vasculitis responsive to dapsone. Br J Dermatol 1996; 135:972.</a></li><li><a class="nounderline abstract_t">Seybold H, Simon M, Schuler G, Lüftl M. [Refractory cutaneous necrotizing vasculitis. Successful sulfone therapy]. Hautarzt 2006; 57:47.</a></li><li><a class="nounderline abstract_t">Wells GC. Allergic vasculitis(tri-symptom of Gougerot) treated with dapsone. Proc R Soc Med 1969; 62:665.</a></li><li><a class="nounderline abstract_t">Fortson JS, Zone JJ, Hammond ME, Groggel GC. Hypocomplementemic urticarial vasculitis syndrome responsive to dapsone. J Am Acad Dermatol 1986; 15:1137.</a></li><li><a class="nounderline abstract_t">Nürnberg W, Grabbe J, Czarnetzki BM. Urticarial vasculitis syndrome effectively treated with dapsone and pentoxifylline. Acta Derm Venereol 1995; 75:54.</a></li><li><a class="nounderline abstract_t">Eiser AR, Singh P, Shanies HM. Sustained dapsone-induced remission of hypocomplementemic urticarial vasculitis--a case report. Angiology 1997; 48:1019.</a></li><li><a class="nounderline abstract_t">Muramatsu C, Tanabe E. Urticarial vasculitis: response to dapsone and colchicine. J Am Acad Dermatol 1985; 13:1055.</a></li><li><a class="nounderline abstract_t">Ruiz Villaverde R, Blasco Melguizo J, Martin Sanchez MC, Naranjo Sintes R. Annular leucocytoclastic vasculitis: response to dapsone. J Eur Acad Dermatol Venereol 2002; 16:544.</a></li><li><a class="nounderline abstract_t">Nürnberg W, Grabbe J, Czarnetzki BM. Synergistic effects of pentoxifylline and dapsone in leucocytoclastic vasculitis. Lancet 1994; 343:491.</a></li><li><a class="nounderline abstract_t">Haeberle MT, Adams WB, Callen JP. Treatment of severe cutaneous small-vessel vasculitis with mycophenolate mofetil. Arch Dermatol 2012; 148:887.</a></li><li><a class="nounderline abstract_t">Nikibakhsh AA, Mahmoodzadeh H, Karamyyar M, et al. Treatment of complicated henoch-schönlein purpura with mycophenolate mofetil: a retrospective case series report. Int J Rheumatol 2010; 2010:254316.</a></li><li><a class="nounderline abstract_t">Worm M, Sterry W, Kolde G. Mycophenolate mofetil is effective for maintenance therapy of hypocomplementaemic urticarial vasculitis. Br J Dermatol 2000; 143:1324.</a></li><li><a class="nounderline abstract_t">Chen KR, Carlson JA. Clinical approach to cutaneous vasculitis. Am J Clin Dermatol 2008; 9:71.</a></li><li><a class="nounderline abstract_t">Heurkens AH, Westedt ML, Breedveld FC. Prednisone plus azathioprine treatment in patients with rheumatoid arthritis complicated by vasculitis. Arch Intern Med 1991; 151:2249.</a></li><li><a class="nounderline abstract_t">Callen JP, Kalbfleisch S. Urticarial vasculitis: a report of nine cases and review of the literature. Br J Dermatol 1982; 107:87.</a></li><li><a class="nounderline abstract_t">Callen JP, Spencer LV, Burruss JB, Holtman J. Azathioprine. An effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol 1991; 127:515.</a></li><li><a class="nounderline abstract_t">Upchurch KS, Heller K, Bress NM. Low-dose methotrexate therapy for cutaneous vasculitis of rheumatoid arthritis. J Am Acad Dermatol 1987; 17:355.</a></li><li><a class="nounderline abstract_t">Gansauge S, Breitbart A, Rinaldi N, Schwarz-Eywill M. Methotrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease). Ann Rheum Dis 1997; 56:382.</a></li><li><a class="nounderline abstract_t">Williams HC, Pembroke AC. Methotrexate in the treatment of vasculitic cutaneous ulceration in rheumatoid arthritis. J R Soc Med 1989; 82:763.</a></li><li><a class="nounderline abstract_t">Espinoza LR, Espinoza CG, Vasey FB, Germain BF. Oral methotrexate therapy for chronic rheumatoid arthritis ulcerations. J Am Acad Dermatol 1986; 15:508.</a></li><li><a class="nounderline abstract_t">Halevy S, Giryes H, Avinoach I, et al. Leukocytoclastic vasculitis induced by low-dose methotrexate: in vitro evidence for an immunologic mechanism. J Eur Acad Dermatol Venereol 1998; 10:81.</a></li><li><a class="nounderline abstract_t">Torner O, Ruber C, Olive A, Tena X. Methotrexate related cutaneous vasculitis. Clin Rheumatol 1997; 16:108.</a></li><li><a class="nounderline abstract_t">Simonart T, Durez P, Margaux J, et al. Cutaneous necrotizing vasculitis after low dose methotrexate therapy for rheumatoid arthritis: a possible manifestation of methotrexate hypersensitivity. Clin Rheumatol 1997; 16:623.</a></li><li><a class="nounderline abstract_t">Tosca A, Ioannidou DJ, Katsantonis JC, Kyriakis KP. Cyclosporin A in the treatment of cutaneous vasculitis.  Clinical and cellular effects. J Eur Acad Dermatol Venerol 1996; 6:135.</a></li><li><a class="nounderline abstract_t">Houck HE, Kauffman CL, Casey DL. Minocycline treatment for leukocytoclastic vasculitis associated with rheumatoid arthritis. Arch Dermatol 1997; 133:15.</a></li><li><a class="nounderline abstract_t">Swaminath A, Magro CM, Dwyer E. Refractory urticarial vasculitis as a complication of ulcerative colitis successfully treated with rituximab. J Clin Rheumatol 2011; 17:281.</a></li><li><a class="nounderline abstract_t">Plotkin GR, Patel BR, Shah VN. Behçet's syndrome complicated by cutaneous leukocytoclastic vasculitis. Response to prednisone and chlorambucil. Arch Intern Med 1985; 145:1913.</a></li><li><a class="nounderline abstract_t">Ong CS, Benson EM. Successful treatment of chronic leucocytoclastic vasculitis and persistent ulceration with intravenous immunoglobulin. Br J Dermatol 2000; 143:447.</a></li></ol></div><div id="topicVersionRevision">Topic 13785 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23045170" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29136340" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Nomenclature of Cutaneous Vasculitis: Dermatologic Addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16426368" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Primary cutaneous small vessel vasculitis: approach to diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25065012" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Single-organ cutaneous small-vessel vasculitis according to the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides: a study of 60 patients from a series of 766 cutaneous vasculitis cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16966021" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cutaneous vasculitis: diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9810883" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Cutaneous small-vessel vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1505105" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Elimination diet in the treatment of selected patients with hypersensitivity vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9217569" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clinical features and outcome of 95 patients with hypersensitivity vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12637912" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Cutaneous vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6754776" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The clinical and histopathologic spectrums of urticarial vasculitis: study of forty cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3603105" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cutaneous leukocytoclastic vasculitis: clinical experience in 44 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/352270" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Chronic urticaria-like lesions in systemic lupus erythematosus. A review of 12 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7062504" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Chronic, recurrent small-vessel cutaneous vasculitis. Clinical experience in 13 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28088991" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prevention and management of glucocorticoid-induced side effects: A comprehensive review: Ocular, cardiovascular, muscular, and psychiatric side effects and issues unique to pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28088990" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prevention and management of glucocorticoid-induced side effects: A comprehensive review: Infectious complications and vaccination recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27986133" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prevention and management of glucocorticoid-induced side effects: A comprehensive review: Gastrointestinal and endocrinologic side effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27986132" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Prevention and management of glucocorticoid-induced side effects: A comprehensive review: A review of glucocorticoid pharmacology and bone health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7492128" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Colchicine in the treatment of cutaneous leukocytoclastic vasculitis. Results of a prospective, randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/507883" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Management of necrotizing vasculitis with colchicine. Improvement in patients with cutaneous lesions and Behcet's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4044947" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Colchicine is effective in controlling chronic cutaneous leukocytoclastic vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2818661" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Colchicine and leukocytoclastic vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4004306" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Urticarial vasculitis treated with colchicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3571541" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Sulfone therapy in the treatment of leukocytoclastic vasculitis. Report of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8977722" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Recurrent annular erythema with purpura: a new variant of leucocytoclastic vasculitis responsive to dapsone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15662534" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : [Refractory cutaneous necrotizing vasculitis. Successful sulfone therapy].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5803501" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Allergic vasculitis(tri-symptom of Gougerot) treated with dapsone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3771868" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Hypocomplementemic urticarial vasculitis syndrome responsive to dapsone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7747536" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Urticarial vasculitis syndrome effectively treated with dapsone and pentoxifylline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9373057" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Sustained dapsone-induced remission of hypocomplementemic urticarial vasculitis--a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4078096" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Urticarial vasculitis: response to dapsone and colchicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12428865" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Annular leucocytoclastic vasculitis: response to dapsone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7906000" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Synergistic effects of pentoxifylline and dapsone in leucocytoclastic vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22911181" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Treatment of severe cutaneous small-vessel vasculitis with mycophenolate mofetil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20628492" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Treatment of complicated henoch-schönlein purpura with mycophenolate mofetil: a retrospective case series report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11122046" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Mycophenolate mofetil is effective for maintenance therapy of hypocomplementaemic urticarial vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18284262" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Clinical approach to cutaneous vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1953230" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Prednisone plus azathioprine treatment in patients with rheumatoid arthritis complicated by vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7104212" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Urticarial vasculitis: a report of nine cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2006876" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Azathioprine. An effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3624579" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Low-dose methotrexate therapy for cutaneous vasculitis of rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9227169" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Methotrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2614773" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Methotrexate in the treatment of vasculitic cutaneous ulceration in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3760277" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Oral methotrexate therapy for chronic rheumatoid arthritis ulcerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9552765" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Leukocytoclastic vasculitis induced by low-dose methotrexate: in vitro evidence for an immunologic mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9132315" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Methotrexate related cutaneous vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9456017" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Cutaneous necrotizing vasculitis after low dose methotrexate therapy for rheumatoid arthritis: a possible manifestation of methotrexate hypersensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Cyclosporin A in the treatment of cutaneous vasculitis.  Clinical and cellular effects</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9006367" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Minocycline treatment for leukocytoclastic vasculitis associated with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21778903" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Refractory urticarial vasculitis as a complication of ulcerative colitis successfully treated with rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4037953" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Behçet's syndrome complicated by cutaneous leukocytoclastic vasculitis. Response to prednisone and chlorambucil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10951164" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Successful treatment of chronic leucocytoclastic vasculitis and persistent ulceration with intravenous immunoglobulin.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
